Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Modafinil for Fatigue in MS
Neurol 64:1139-1143, Stankoff,B.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Randomized Controlled Trial of Yoga and Exercise in Multiple Sclerosis
Neurol 62:2058-2064, Oken,B.S.,et al, 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS
Neurol 58:1404-1407,1323, Killestein,J.,et al, 2002
Efficacy and Safety of Modafinil (Provigil) for the Treatment of Fatigue in Multiple Sclerosis: A Two Centre Phase 2 Study
JNNP 72:179-183,150, Rammohan,K.W.,et al, 2002
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Gastric Tolerance of High-Dose Pulse Oral Prednisone in Multiple Sclerosis
Neurol 53:2093-2096, Metz,L.M.,et al, 1999
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Tizanidine for Spasticity
The Medical Letter 39:62, , 1997
Impact of Aerobic Training on Fitness and Quality of Life in Multiple Sclerosis
Ann Neurol 39:432-441, 4221996., Petajan,J.H.,et al, 1996
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996
Tizanidine Treatment of Spasticity Caused by Multiple Sclerosis:Results of a Double-Blinded, Placebo-Controlled Trial
Neurol 44:S34-S43, Smith,C.,et al, 1994
A Double-Blind, Placebo-Controlled Trial of Tizanidine in the Treatment of Spasticity Caused by Multiple Sclerosis
Neurol 44:S70-S78, Barnes,M.P.,et al, 1994
A Double-Blind, Renadomized, Crossover Trial of Pemoline in Fatigue Assoc with Multiple Sclerosis
Neurol 42:1468-1471, Weinshenker,B.G.,et al, 1992
Treatment of Spasticity with Botulinum Toxin:A Double-Blind Study
Ann Neurol 28:512-515, Snow,B.J.,et al, 1990
Amantadine Treatment of Fatigue Associated with Multiple Sclerosis
Arch Neurol 46:676-680, Cohen,R.A.&Fisher,M., 1989
Intrathecal Baclofen for Severe Spinal Spasticity
NEJM 320:1517-1521, 1553-15551989., Penn,R.D.,et al, 1989
Intrathecal Baclofen for Long-Term Treatment of Spasticity:A Multi-Centre Study
JNNP 52:933-939, Ochs,G.,et al, 1989
Amantadine, Fatigue, and Multiple Sclerosis
Arch Neurol 45:1104-1106, Rosenberg,G.A.&Appenzeller,O., 1988
Continuous Intrathecal Baclofen for Severe Spasticity
Lancet 2:125-127, Penn,R.D.&Kroin,J.S., 1985
Baclofen for Spasticity in Multiple Sclerosis
Neurol 28:1094-1098, Feldman,R.G.,et al, 1978
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975